Previous studies have shown that PTS inhibits the expression of epidermal growth factor receptor, thereby reducing p-Akt levels, which leads to decreased activation of the G- and S-phases of the cell cycle, ultimately inhibiting the proliferation of lung cancer cells. The gene discussed is EGFR; the disease is lung carcinoma.